Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
6.07
+0.12 (2.02%)
At close: Jun 18, 2026, 4:00 PM EDT
6.11
+0.04 (0.66%)
After-hours: Jun 18, 2026, 7:11 PM EDT
Decoy Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
3.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 852.28K |
| Onconetix | 735.20K |
| VivoSim Labs | 142.00K |
| Azitra | 7.50K |
| Virax Biolabs Group | 2.99K |
DCOY News
- 6 days ago - Decoy Therapeutics Registration statement: Registration filing - Filings
- 6 days ago - Decoy Therapeutics files to sell 808,000 shares of common stock for holders - TheFly
- 12 days ago - Decoy Therapeutics Inc trading resumes - TheFly
- 12 days ago - Decoy Therapeutics Inc trading halted, volatility trading pause - TheFly
- 13 days ago - Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London - PRNewsWire
- 17 days ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 17 days ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 18 days ago - Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PRNewsWire